0001493152-24-021163.txt : 20240523 0001493152-24-021163.hdr.sgml : 20240523 20240523165441 ACCESSION NUMBER: 0001493152-24-021163 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240523 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240523 DATE AS OF CHANGE: 20240523 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardion Health Sciences, Inc. CENTRAL INDEX KEY: 0001642375 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474428421 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38861 FILM NUMBER: 24979254 BUSINESS ADDRESS: STREET 1: 2925 RICHMOND AVENUE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 BUSINESS PHONE: (800) 873-5141 MAIL ADDRESS: STREET 1: 2925 RICHMOND AVENUE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 FORMER COMPANY: FORMER CONFORMED NAME: Guardion Health Sciences, LLC DATE OF NAME CHANGE: 20150513 8-K 1 form8-k.htm
false 0001642375 0001642375 2024-05-23 2024-05-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 23, 2024

 

GUARDION HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38861   47-4428421

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

2925 Richmond Avenue, Suite 1200

Houston, Texas 77098

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (800) 873-5141

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   GHSI   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On May 23, 2024, Guardion Health Sciences, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, the Company’s stockholders considered the following proposals: (i) the sale of all of the outstanding equity interests (the “Transaction”) of Activ Nutritional, LLC (“Activ”), a Delaware limited liability company which owns the Viactiv® brand and business and is the wholly-owned subsidiary of Viactiv Nutritionals, Inc (“Viactiv”), a Delaware corporation and a wholly-owned subsidiary of the Company, pursuant to an Equity Purchase Agreement with Doctor’s Best Inc., a Delaware corporation (“Doctor’s Best”), dated January 30, 2024 (the “Purchase Agreement”); and (ii) the grant of discretionary authority to the Board of Directors of the Company (the “Board”) to adjourn the Special Meeting to a later date (the “Adjournment Proposal”), to allow for the solicitation of additional proxies only in the event that there are insufficient shares present virtually or represented by proxy voting in favor of the Transaction or the voluntary dissolution and liquidation of the Company (the “Dissolution”) pursuant to a Plan of Dissolution (the “Plan of Dissolution”), which, if approved, will authorize the Company to liquidate and dissolve the Company in accordance with the Plan of Dissolution, but subject to the Company’s ability to abandon or delay the Plan of Dissolution in accordance with the terms thereof (the “Dissolution Proposal”) .

 

Stockholders of record at the close of business on April 5, 2024 (the “Record Date”) were entitled to notice of and one vote for each share of common stock held by such stockholder. On the Record Date, there were 1,284,156 shares of common stock issued and outstanding, of which 690,059 shares of common stock were represented at the Special Meeting, or approximately 53.73% of the total outstanding shares of common stock on the Record Date, which was sufficient to constitute a quorum pursuant to the Company’s Second Amended and Restated Bylaws, as amended, and to transact business.

 

Set forth below are the final voting results for the proposals:

 

Proposal No. 1 – Sale of Activ

 

The Transaction was approved by the stockholders. The voting results were as follows:

 

Votes For  Votes Against   Abstentions   Broker Non-Votes 
652,867   36,822    370    0 

 

Proposal No. 3 – Adjournment of Special Meeting

 

As there were not sufficient votes to approve the Dissolution Proposal (Proposal No. 2), the Dissolution Proposal was not presented to the stockholders for their consideration at the Special Meeting. Consequently, the Adjournment Proposal (Proposal 3) was presented to the stockholders for their consideration at the Special Meeting and was approved. The voting results were as follows:

 

Votes For  Votes Against   Abstentions   Broker Non-Votes 
635,846   52,190    2,023    0 

 

In accordance with the authority granted pursuant to the Adjournment Proposal, the Special Meeting was adjourned to 11:00 a.m. Central Time on May 31, 2024, to allow management to solicit additional proxies in favor of the Dissolution Proposal.

 

 
 

 

Item 8.01 Other Events.

 

In connection with stockholder approval of the Transaction and the Adjournment Proposal obtained at the Special Meeting, on May 23, 2024, the Company issued a press release announcing stockholder approval of the Transaction and adjournment of the Special Meeting to 11:00 a.m. Central Time on May 31, 2024.

 

The information in this Item 8.01 and Exhibit 99.1 hereto shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference into any Company filing, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Additional Information and Where to Find It

 

On January 30, 2024, the Company the Purchase Agreement with Doctor’s Best for the sale of all of the outstanding equity interests of Activ for aggregate cash consideration of $17.2 million, of which $1.7 million was placed in a third-party escrow account pursuant to the terms of the Purchase Agreement. Doctor’s Best Inc. is a wholly-owned subsidiary of Kingdomway USA Corp., the U.S. subsidiary holding company of Xiamen Kingdomway Group Company, which is publicly listed on the Shenzhen Stock Exchange.

 

In the event that the transaction closes, the Company would be left with minimal operations. Accordingly, the Board has determined that it is advisable and in the best interests of the Company and its stockholders to approve a voluntary dissolution and liquidation of the Company pursuant to a Plan of Liquidation and Dissolution, which, if approved, would authorize the Company to liquidate and dissolve in accordance with its terms, but such decision would be subject to the Company’s ability to abandon or delay the Plan of Liquidation and Dissolution in the event that the Board determines that another transaction would be in the best interests of the Company’s stockholders. Assuming the approval of the Plan of Liquidation and Dissolution by the Company’s stockholders, the decision as to whether or not to proceed with the dissolution and when to file the Certificate of Dissolution will be made by the Board in its sole discretion.

 

In connection with the Purchase Agreement and the proposed transactions, the Company filed a definitive proxy statement with the SEC, which was distributed to the stockholders of the Company in connection with its solicitation of proxies for the vote by its stockholders with respect to the proposed transactions and other matters as may be described in the definitive proxy statement. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY’S DEFINITIVE PROXY STATEMENT AND ACCOMPANYING PROXY CARD, AND ANY SUPPLEMENTS THERETO, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and stockholders are able to obtain a copy of the definitive proxy statement and other relevant documents filed by the Company with the SEC free of charge from the SEC’s website, www.sec.gov., or by visiting the investor relations section of the Company’s website, investors.guardionhealth.com. Stockholders may also request copies of proxy statements and any of the documents incorporated by reference by directing a request by mail to Guardion Health Sciences, Inc., Attention: Investor Relations, at 2925 Richmond Avenue, Suite 1200, Houston, Texas 77098.

 

Participants in the Solicitation

 

The Company and its executive officers, directors, other members of management, and employees may be deemed, under SEC rules, to be participants in the solicitation of proxies from the Company’s stockholders with respect to the proposed transaction. Information regarding the executive officers and directors of the Company is set forth in the Proxy Statement filed with the SEC on April 8, 2024.

 

 
 

 

Forward-Looking Statements

 

The matters described herein may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions regarding our product development and commercialization efforts, research and development efforts, business, financial condition, results of operations, strategies or prospects, and other similar matters. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” “hopes” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing.

 

These statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, and involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the approval by the stockholders of the Plan of Liquidation and Dissolution of the Company, the successful completion of the sale of Activ to Doctor’s Best Inc., the successful completion of the Company’s Plan of Liquidation and Dissolution if approved by the Company’s stockholders, the use of the proceeds received from the sale, the Company’s ability to continue to fund or wind-down its operations, including its ocular healthcare business, subsequent to the sale, any replacement and integration of new management team members if needed, the implementation of new financial, management, accounting and business software systems, supply chain disruptions, key retail and e-commerce disruptions, inflation and a potential recession on the Company’s business, operations and the economy in general, the Company’s ability to successfully develop and commercialize its proprietary products and technologies, and the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements.

 

Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No.   Exhibit
99.1   Press release dated May 23, 2024
104   Cover Page Interactive Data File (embedded within the XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

GUARDION HEALTH SCIENCES, INC.

(Registrant)

Date: May 23, 2024    
  By: /s/ Jan Hall
  Name: Jan Hall
  Title: Chief Executive Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Guardion Health Sciences Announces Approval by Stockholders of Proposed Sale of Viactiv Business

 

Adjourns Special Meeting to May 31, 2024 in order to Solicit Additional Proxies in Support of its Plan of Liquidation and Dissolution

 

HOUSTON, TEXAS – May 23, 2024 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced today that its stockholders approved the previously announced sale of its Viactiv business at a special meeting (the “Meeting”) held earlier today. Following this approval, the Company then adjourned the Meeting to 11:00 a.m. Central Time on May 31, 2024 in order to give the Company’s management additional time to solicit proxies from its stockholders of record on April 5, 2024 to vote in favor of the proposal to adopt the Company’s Plan of Liquidation and Dissolution, as described in the Company’s definitive proxy statement filed with the United States Securities and Exchange Commission on April 8, 2024. The Company needs to obtain approval from a majority of its shares of common stock issued and outstanding for the proposal to pass.

 

Robert N. Weingarten, Chairman of the Board of Directors, stated: “We appreciate the support of our stockholders in approving the sale of our Viactiv business. We continue to work toward the closing of the Viactiv transaction and expect that the closing will occur by June 30, 2024. We also appreciate the support of our stockholders who have voted overwhelmingly in support of our Plan of Liquidation and Dissolution and are hopeful this additional week to solicit votes will cause our stockholders who have not yet voted to vote in favor of this proposal. We continue to believe that the closing of the Viactiv transaction, followed by an orderly and efficient wind-down of the Company, so we can distribute the expected accumulated cash to our stockholders, is the best result for our stockholders. As described in our definitive proxy statement, under the Plan of Liquidation and Dissolution, the Board maintains the flexibility to abandon the dissolution if an alternative transaction proposal becomes available that would be a better result for our stockholders.”

 

If stockholders wish to vote or have any questions or need assistance, please call the Company’s proxy solicitor:

 

Kingsdale Advisors

North American Toll-Free Phone: 1-866-229-8874

Email: contactus@kingsdaleadvisors.com

745 Fifth Avenue, 5th Floor, New York, New York 10151

 

Agreement to Sell Activ Nutritional, LLC

 

As previously announced, on January 30, 2024, the Company entered into an Equity Purchase Agreement (the “Purchase Agreement”) with Doctor’s Best Inc., a Delaware corporation, for the sale of all of the outstanding equity interests of Activ Nutritional, LLC (“Activ”) for aggregate cash consideration of $17,200,000, of which $1,700,000 was placed in a third-party escrow account pursuant to the terms of the Purchase Agreement. Doctor’s Best Inc. is a wholly-owned subsidiary of Kingdomway USA Corp., the U.S. subsidiary holding company of Xiamen Kingdomway Group Company (“XKDW”), which is publicly listed on the Shenzhen Stock Exchange. This transaction is the result of a broad review of strategic alternatives by the Company’s Board of Directors over the past year.

 

Potential Dissolution

 

In the event that the transaction closes, the Company would be left with minimal operations. The Board of Directors has additionally determined that it is in the best interests of the Company and its stockholders to approve a voluntary dissolution and liquidation of the Company pursuant to a Plan of Liquidation and Dissolution, which would authorize the Company to liquidate and dissolve in accordance with its terms. However, such decision would be subject to the Company’s ability to abandon or delay the Plan of Liquidation and Dissolution in the event that the Board of Directors determines that another transaction would be in the best interests of the Company’s stockholders.

 

 
 

 

Views and Recommendations of the Board of Directors

 

If both of these proposals are approved and the Viactiv transaction closes in accordance with its terms, stockholders would receive one or more liquidating cash distributions, which combined are expected to be between $9.00 and $11.00 per share of common stock as described in the Company’s Current Report on Form 8-K dated May 21, 2024.

 

If the dissolution proposal is not approved and/or the Viactiv transaction does not close in accordance with its terms, we believe that there is substantial risk to the value of the Company’s shares.

 

Accordingly, the Board of Directors unanimously and strongly recommends that stockholders vote FOR the dissolution proposal. The transaction remains on track for completion by June 30, 2024, subject to satisfaction or waiver of customary closing conditions.

 

If stockholders approve the sale of Activ but do not approve the Plan of Liquidation and Dissolution, the Company believes it will be more difficult for the Company to expeditiously distribute the maximal amount of cash from that sale to our stockholders, since the Company will need to retain cash to continue to fund the considerable on-going expenses it has as a public company and to operate its remaining ocular healthcare business while the Board of Directors considers strategic alternatives.

 

The Company’s common stock is listed and traded on the Nasdaq Capital Market (“Nasdaq”) under the symbol “GHSI”. However, if the sale of Activ is approved but the Plan of Liquidation and Dissolution of the Company is not approved, we believe that maintaining our listing on Nasdaq will be difficult and uncertain.

 

Shares that are not voted are the same as a “NO” vote for each proposal, so every vote matters, regardless of how many shares a stockholder may own.

 

About Guardion Health Sciences, Inc.

 

Guardion Health Sciences, Inc. (Nasdaq: GHSI) is a clinical nutrition company that offers a portfolio of science-based, clinically supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients. Information and risk factors with respect to Guardion and its business may be obtained in the Company’s filings with the SEC at www.sec.gov.

 

Additional Information and Where to Find it

 

In connection with the proposed sale of Activ and the Plan of Liquidation and Dissolution, the Company filed with the SEC a Definitive Proxy Statement and other relevant documents, including a form of proxy card, on April 8, 2024, which were mailed to the Company’s stockholders of record on April 5, 2024. Stockholders are urged to read the Definitive Proxy Statement and any other documents filed with the SEC in connection with the proposed sale of Activ and the Plan of Liquidation and Dissolution, or incorporated by reference in the Definitive Proxy Statement because they contain important information. The Company’s filings with the SEC may be obtained without charge at www.sec.gov.

 

Participants in the Solicitation

 

The Company and its executive officers, directors, other members of management, and employees may be deemed, under SEC rules, to be participants in the solicitation of proxies from the Company’s stockholders with respect to the proposed transactions. Information regarding the executive officers and directors of the Company is set forth in the Company’s definitive proxy statement.

 

 
 

 

Forward-Looking Statements

 

The matters described herein may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions regarding our product development and commercialization efforts, research and development efforts, business, financial condition, results of operations, strategies or prospects, and other similar matters. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” “hopes” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing.

 

These statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, and involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the approval by the stockholders of the Plan of Liquidation and Dissolution of the Company, the successful completion of the sale of Activ to Doctor’s Best Inc., the successful completion of the Company’s Plan of Liquidation and Dissolution if approved by the Company’s stockholders, the use of the proceeds received from the sale, the Company’s ability to continue to fund or wind-down its operations, including its ocular healthcare business, subsequent to the sale, any replacement and integration of new management team members if needed, the implementation of new financial, management, accounting and business software systems, supply chain disruptions, key retail and e-commerce disruptions, inflation and a potential recession on the Company’s business, operations and the economy in general, the Company’s ability to successfully develop and commercialize its proprietary products and technologies, and the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements.

 

Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For more information about Guardion Health Sciences, Inc., Contact:

 

investors@guardionhealth.com

Phone: 1-800 873-5141 Ext 208

 

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 ghsi-20240523.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 ghsi-20240523_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 ghsi-20240523_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
May 23, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 23, 2024
Entity File Number 001-38861
Entity Registrant Name GUARDION HEALTH SCIENCES, INC.
Entity Central Index Key 0001642375
Entity Tax Identification Number 47-4428421
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2925 Richmond Avenue
Entity Address, Address Line Two Suite 1200
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77098
City Area Code (800)
Local Phone Number 873-5141
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol GHSI
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://guardionhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ghsi-20240523.xsd ghsi-20240523_lab.xml ghsi-20240523_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "GHSI", "nsuri": "http://guardionhealth.com/20240523", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "ghsi-20240523.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ghsi-20240523_lab.xml" ] }, "presentationLink": { "local": [ "ghsi-20240523_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://guardionhealth.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-23", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-23", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001493152-24-021163-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-021163-xbrl.zip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end XML 18 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001642375 2024-05-23 2024-05-23 iso4217:USD shares iso4217:USD shares false 0001642375 8-K 2024-05-23 GUARDION HEALTH SCIENCES, INC. DE 001-38861 47-4428421 2925 Richmond Avenue Suite 1200 Houston TX 77098 (800) 873-5141 false false false false Common Stock, par value $0.001 per share GHSI NASDAQ true false